- Wegovy should be stopped at least 2 months before planned conception
- Weight loss from GLP-1 medication can improve fertility, which means pregnancy may occur sooner than expected
- Work with your clinician to plan a safe transition off medication
- PEAK supports patients through the full lifecycle including pregnancy planning
If you are taking Wegovy and thinking about becoming pregnant, this is a conversation to have with your clinician now — not later. Semaglutide is not safe to use during pregnancy, and the medication requires time to leave your body before conception. The good news is that with proactive planning, the transition can be smooth, safe, and well-supported.
This guide covers what you need to know about Wegovy and pregnancy: when to stop, why the timing matters, how weight loss can affect fertility, and how to plan the transition with your care team.
Wegovy is not recommended during pregnancy
Semaglutide is contraindicated in pregnancy. Animal studies have shown adverse effects on embryonic development, and there are no adequate studies in pregnant humans. Because of this, the FDA classifies semaglutide as a medication that should not be used during pregnancy.
Beyond the direct risks of the medication itself, intentional weight loss during pregnancy is not recommended. Pregnancy requires adequate caloric intake and nutrition to support fetal development. Wegovy works in part by reducing appetite and caloric intake — the opposite of what a developing pregnancy needs.
The pregnancy contraindication is not unique to Wegovy. It applies to all semaglutide products (including Ozempic) as well as tirzepatide (Zepbound and Mounjaro). If you are on any GLP-1 medication and considering pregnancy, the same guidance applies.
When to stop Wegovy
The FDA and the manufacturer (Novo Nordisk) recommend discontinuing Wegovy at least 2 months before a planned conception. This is not an arbitrary number — it is based on the pharmacokinetics of semaglutide and the time required for the drug to be substantially cleared from your system.
In practice, this means that if you are actively trying to conceive or planning to start trying in the near future, you should be having this conversation with your clinician now. The 2-month timeline is a minimum, and your clinician may recommend a longer washout depending on your individual circumstances.
Minimum: Stop Wegovy at least 2 months (approximately 8 weeks) before planned conception.
Recommended: Discuss your pregnancy timeline with your clinician as early as possible so you can plan the transition together.
If pregnancy occurs while on Wegovy: Stop the medication immediately and contact your healthcare provider.
Why the washout period matters
Semaglutide has a long half-life of approximately 7 days. This means that after your last injection, it takes about a week for the concentration in your blood to drop by half. After 5 half-lives (approximately 5 weeks), the medication is considered to be substantially cleared from your body.
The 2-month recommendation provides an additional safety margin beyond the 5-week pharmacological clearance window. This accounts for individual variation in metabolism and ensures that semaglutide levels are negligible by the time conception occurs.
The washout period is not about inconvenience — it is about giving your body the time it needs to be medication-free before supporting a pregnancy.
During this washout period, you may notice changes in your appetite, energy levels, and weight. This is expected and something your clinician can help you manage. The goal is to maintain the healthy habits you have built while on medication, even as the pharmacological support is removed.
Fertility considerations
Here is something many patients do not expect: weight loss from GLP-1 medications can significantly improve fertility. This is particularly relevant for patients with polycystic ovary syndrome (PCOS), a condition closely linked to excess weight and insulin resistance.
- Improved ovulation. Weight loss can restore regular ovulatory cycles in patients with PCOS or obesity-related anovulation. Even a modest weight loss of 5–10% of body weight can be enough to trigger this change.
- Hormonal rebalancing. Excess adipose tissue produces estrogen and affects other reproductive hormones. As weight decreases, hormonal balance often improves.
- Better insulin sensitivity. GLP-1 medications improve insulin sensitivity directly, and this effect is compounded by weight loss. Improved insulin sensitivity is strongly associated with improved fertility in PCOS patients.
- Improved IVF outcomes. For patients pursuing assisted reproduction, being at a healthier weight is associated with better treatment outcomes.
This is critical to understand: if you have been struggling with fertility due to weight or PCOS, the weight loss from Wegovy may restore your fertility faster than anticipated. If you are not ready for pregnancy, discuss contraception with your clinician. Unplanned pregnancy while still on semaglutide is exactly the situation you want to avoid.
Planning the transition
Stopping Wegovy is not something you should do abruptly without a plan. Work with your clinician to create a structured discontinuation strategy that protects both your progress and your pregnancy goals.
Create a discontinuation timeline
Your clinician may recommend a gradual step-down rather than an abrupt stop, depending on your current dose and how long you have been on the medication. This can help ease the transition and reduce the likelihood of rebound appetite changes.
Nutritional support during transition
As the appetite-suppressing effects of semaglutide wear off, your appetite will likely return closer to its pre-medication baseline. This is normal. The key is to have a nutritional framework in place before this happens:
- Work with your care team to establish a sustainable eating plan that supports your weight maintenance goals and prepares your body for pregnancy.
- Focus on nutrient-dense foods that support fertility: folate, iron, omega-3 fatty acids, and adequate protein.
- Begin prenatal vitamins before conception — ideally at least one month before you start trying.
- Stay hydrated and maintain regular meal timing to help manage appetite changes.
Maintaining healthy habits without medication
The behavioral changes you made while on Wegovy — portion awareness, food choices, physical activity — are habits that can persist after the medication stops. Your PEAK care team will help you identify which strategies are sustainable long-term and which may need reinforcement as the pharmacological support is removed.
Structured timeline. A clear schedule for discontinuation coordinated with your conception goals.
Nutritional guidance. Pre-pregnancy dietary recommendations specific to your needs.
Monitoring. Regular check-ins to track weight stability, appetite changes, and overall wellbeing during the transition.
Behavioral support. Strategies to maintain healthy habits without pharmacological assistance.
After pregnancy
Many patients want to know whether they can resume Wegovy after delivery. In most cases, the answer is yes — but the timing depends on several factors.
When you can resume
Your clinician will evaluate the right time to restart based on your postpartum recovery, overall health, and individual circumstances. There is no universal timeline — it is a decision made between you and your care team.
Breastfeeding considerations
Semaglutide is not recommended during breastfeeding. It is not known whether semaglutide passes into breast milk, and the effects on a nursing infant have not been studied. If you plan to breastfeed, your clinician will factor this into the timeline for resuming medication.
This does not mean you are without options. Your PEAK care team can support your postpartum weight management through nutritional guidance, behavioral strategies, and monitoring while you are breastfeeding. Once breastfeeding is complete, resuming GLP-1 therapy can be discussed.
Postpartum weight management
Postpartum weight management is a unique challenge, and it deserves a thoughtful approach. Rushing back to medication is not always the right answer. Your body has been through a significant physiological event, and your care plan should reflect that.
- Focus on recovery first — adequate nutrition, rest, and physical healing take priority.
- Gradual return to physical activity as cleared by your OB/GYN.
- Nutritional support that accounts for breastfeeding caloric needs if applicable.
- When the time is right, your PEAK team can help you evaluate whether resuming Wegovy or another GLP-1 medication is the best path forward.
Talk to your clinician
The most important takeaway from this article is simple: this is a conversation to have proactively, not reactively. If pregnancy is anywhere on your horizon — either actively planned or simply a future possibility — bring it up with your PEAK care team now.
Proactive planning means:
- No surprises. You will have a clear timeline and a structured plan for discontinuation.
- Protected progress. Your weight loss achievements do not have to be lost during the transition. With the right support, you can maintain your results.
- Safe conception. Adequate washout time means semaglutide will be cleared from your system before pregnancy begins.
- Contraception awareness. If you are not ready for pregnancy but your fertility is improving, your clinician can help you make informed decisions about contraception.
The best time to plan your transition is before you need to. A proactive conversation today prevents a reactive scramble later.
At PEAK, we support patients through the full lifecycle of their weight management process — including the pauses. Pregnancy planning is not an interruption to your care. It is part of it. We will help you manage the transition safely and be here when you are ready to resume.
Important safety information: Wegovy carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
